X

Articles

10Jul

FDA Guidance for Industry for Babesia

0 Comments | | Return |

On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.

 

Check out the Communication page for the complete details by clicking the link: Communications

Related

CTS to Implement the Grifols Procleix Ultrio Elite Assay Beginning June 1, 2020

Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...

Read More >

Upcoming HCV Testing Algorithm Change

FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...

Read More >

Reminder- Check flights and cargo hours for the New Year's Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral

As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...

Read More >

Dr. Marion Lanteri Joins Creative Testing Solutions as Scientific Affairs VP

TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...

Read More >

Sample submission during the national blood shortage

Through communications with our clients, CTS is aware of the current national blood shortage. We rea...

Read More >